Aytu BioScience ((AYTU)) has held its Q3 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Aytu BioScience’s latest earnings call painted a cautiously optimistic picture as the company pivots toward its new depression treatment, EXXUA. Management highlighted strong early launch momentum and improving access trends, but this progress is being offset by steep declines in legacy product revenue, negative EBITDA, and near-term volatility in margins and cash use as launch investments ramp.
EXXUA Launch Delivers Strong Early Revenue and Script Growth
EXXUA posted $2.4 million in net revenue in its first meaningful commercial quarter, signaling solid demand for a new entrant in depression treatment. Prescriptions rose from about 200 in January to over 700 in March, with April scripts climbing another 26% month over month to more than 920.
Units and Channel Shipments Accelerate Rapidly
Gross unit sales in the quarter reached 3,335, split between 1,807 30-count bottles and 1,528 titration packs, underscoring healthy channel activity. Since launch, cumulative gross units totaled 3,881, and April shipments alone exceeded 1,300 units, a sharp 51% sequential increase versus March.
Prescriber Adoption Broadens Across the U.S.
More than 450 unique prescribers wrote EXXUA during the quarter, capturing roughly 10% to 13% of the company’s initial 3,500 to 4,000 target prescriber universe. Notably, prescriptions have already been written in over 40 states, including markets without a direct field sales presence, suggesting strong word-of-mouth and early clinical interest.
Refill and Titration Trends Suggest Tolerability
Management pointed to early refill activity and high use of titration packs as evidence that patients are staying on therapy and tolerating the drug. They are seeing meaningful conversion from titration packs to 30-day supplies, with refills starting to show despite the small and early patient base.
RxConnect Boosts Access as Payer Coverage Improves
The company’s RxConnect program offers a no-cost 14-day titration pack and guaranteed coverage for the first two months for commercially insured patients, easing adoption hurdles. Within that network, prior authorization approval rates above roughly 70% and improving coverage across commercial, Medicaid and Medicare channels suggest payer dynamics are moving in the right direction.
EXXUA Unit Economics Support Long-Term Margins
Aytu expects EXXUA to deliver attractive unit economics, with cost of goods sold around 31% and a gross contribution margin near 69% before fixed costs. Even after factoring in a 28% royalty and cost-of-goods true-ups, management anticipates mid-to-high-60% gross margins over time as volume scales.
Balance Sheet Strengthened by Warrant Amendments
The company amended certain warrants, reducing derivative warrant liabilities and lifting stockholders’ equity by $26.4 million at quarter end. As a result, equity rose to $35.1 million as of March 31, 2026, which also lowers future noncash earnings volatility linked to warrant accounting.
Total Revenue Declines as Focus Shifts to EXXUA
Despite EXXUA’s ramp, total net revenue fell to $12.4 million from $18.5 million a year earlier, a drop of 33% as the company reallocates resources from legacy products. The transition reflects a strategic bet that EXXUA’s growth can eventually offset declines in older franchises.
Legacy ADHD and Pediatric Portfolios Under Pressure
The ADHD portfolio saw net revenue fall to $9.1 million from $15.4 million, roughly a 41% decline, driven by a smaller sales footprint and new generic competition to Adzenys. Pediatric revenues were hit even harder, dropping to $0.9 million from $3.1 million as payer mix, higher rebates and increased returns weighed on performance.
Profitability Hit by Launch Spend and Legacy Weakness
Aytu swung to a net loss of $5.6 million, or $0.53 per share, compared with net income of $4.0 million in the prior-year quarter, highlighting the earnings drag from the transition. Adjusted EBITDA turned negative $2.8 million versus a positive $3.9 million a year ago, driven primarily by EXXUA launch investments and shrinking legacy revenue.
Inventory Write-Down Dampens Gross Margin
Gross margin slipped to 61% from 69% year over year, as a $700,000 inventory write-down tied to the shift toward an authorized generic for Adzenys weighed on results. Excluding that charge, management said gross margin would have been roughly 67%, indicating the underlying business remains reasonably profitable at the product level.
Cash Use and Planned Spending for EXXUA
Cash and equivalents stood at $26.7 million at March 31, down from $30 million at year-end, reflecting planned investment behind the EXXUA rollout. Looking ahead, the company expects quarterly sales and marketing spending of $6 million to $7 million and G&A of $5 million to $5.3 million, with an additional $1 million to $2 million in Q4 digital marketing and $200,000 to $300,000 in medical education.
Gross-to-Net and Launch Dynamics Create Near-Term Noise
Management cautioned that gross-to-net adjustments are running higher than originally modeled, and may remain volatile in early launch phases. Initiatives such as free titration packs, guaranteed early coverage and initial channel stocking can skew reported net prices and revenue timing, making near-term trends less predictable.
Generic Competition Weighs on Adzenys Franchise
An authorized third-party generic for Adzenys has quickly captured around 14% share in just over four months, exerting pressure on branded ADHD revenues. While RxConnect helps defend some share, the company acknowledged that this competitive backdrop adds to the headwinds facing its legacy portfolio.
Forward-Looking Outlook Centers on EXXUA Scale-Up
Although Aytu did not issue formal numerical guidance, management laid out a framework pointing to EXXUA as the primary growth engine and path to profitability. They expect continued script and unit growth, gross margins in the mid-to-high-60% range over time, and a gradual move toward breakeven as EXXUA expands, supported by disciplined but elevated launch spending and a bolstered balance sheet.
Aytu BioScience’s earnings call underscored a company in transition, leaning into a promising new psychiatric asset while absorbing the financial hit from shrinking legacy franchises. For investors, the story now hinges on whether EXXUA’s accelerating adoption and attractive economics can outpace ongoing revenue declines and near-term margin and cash volatility in the quarters ahead.